Non-invasive Testing for Liver Fibrosis
Webinar Date: 1 April 2022​

Speakers list:

  • Dr Imtiaz Alam, Dr Mona Munteanu, Michael Betel

Webinar Summary:

Liver biopsies versus Non-invasive Tests (NITs), what does the future hold? What are NITs? What are the different types of NITs? What do specific biomarkers indicate? What are the limitations of liver biopsies? Will there be a new ‘gold standard’? The 4 part series on Non-invasive Liver Tests will have our experts share their experience and knowledge about the latest trends and advancements.

Webinar Agenda:

  • PART 1
    • What are NITs?
    • What are the different types of NITs?
    • What do specific biomarkers indicate?
    • What are the limitations of liver biopsies?
    • Will there be a new ‘gold standard’?
  • PART 2
    • What is the role of the Primary Care Physician?
    • What do the NITs tell the Physician?
    • Which of us are most at risk? Who should be referred?
    • Are biopsies a realistic ‘screening’ tool?
    • What are the current EASL guidelines?
    • Who needs to be involved in a multi-disciplinary team?
  • PART 3
    • What are the different types of NITs?
    • What are biomarkers? How do they differ?
    • What are the limitations?
    • What is LIVERFASt?
  • PART 4
    • Learn how LIVERFASt scores can determine disease severity.
    • Learn how one simple blood draw could inform about the fat, the inflammation and the degree of fibrosis in the liver.
    • What is the uniqueness of AI technology?
    • Can cardiovascular risk be reduced?

Speakers:

Dr. Imtiaz Alam
Dr. Imtiaz Alam
Dr. Imtiaz Alam, MD is a gastroenterology specialist in Lubbock, TX. Dr. Alam completed a residency at Univ Ca Sf Sch Of Med, Gastroenterology Lehigh Valley Hosp, Internal Medicine Hahnemann Univ Hosp, Internal Medicine. He currently practices at UMC Southwest Gastroenterology and is affiliated with Ascension Seton Williamson.
Dr. Mona Munteanu
Dr. Mona Munteanu
Dr. Mona Munteanu earned her PhD from the Sorbonne University in Paris, France for her work on the FibroTest in NAFLD and is the Chief Scientific Officer of Fibronostics
Michael Betel
Michael Betel
Michael Betel is the President and Founder of the Fatty Liver Alliance and has been a leader in the area of liver disease, in both commercial and not-for-profit organizations for over 25 years, as a Commercial Director at Hoffmann-La Roche and Canadian Blood Services, and as a sales and marketing leader at Schering-Plough. He was a Director on the board of a national health charity for 9 years.